Immuno-Oncolytic Viruses

In recent years, oncolytic immunotherapy has shown great promise in the fight against cancer. However, it has largely hit a glass ceiling - of specificity and accuracy.


Oncolytic Viruses can recruit the body’s own immune system, and help it fight the malignant tumor cells. They do so through several mechanisms of action: selective replication within neoplastic cells, resulting in a direct lytic effect on tumor cells; induction of systemic antitumor immunity; and indirect mechanisms such as destruction of tumor blood vessels, amplification of specific anti-cancer immune responses or through specific activities of transgene-encoded proteins expressed from engineered viruses.


However, if not sufficiently controlled, Oncolytic Viruses are largely ineffective. While the viruses can help promote an immune response against the tumor cells by allowing tumor antigen presentation in the context of an active viral infection, neutralizing antiviral responses may block virus replication and ongoing infection of tumor cells. 

The therapeutic outcome depends on a complex interplay between these opposing forces, as well as the ability to maximize the transgene expression. 


Therefore, the key challenge for the field is to fine-tune the immune response to maximize both virus spread and anticancer immunity, and to manufacture viruses with orders-of-magnitude higher than is currently possible.


SynVaccine’s technology does exactly that.

Synvaccine's engine is the first fully integrated computer-aided design and manufacturing (CAD/CAM) system for synthetic, rationally designed viruses.


By studying and formulating the natural evolutionary laws of viruses, designing a virus with the desired specifications, and manufacturing it with a unique two-way validation process, SynVaccine is able to fine-tune the selectivity and replication rate of the virus, and control the expressed transgene. The result is highly-accurate Oncolytic Virus.


Oncolytic Immunotherapy has great promise in the fight against cancer, wanting only for for accuracy. Now, SynVaccine is turning it from a blunt apparatus to a precise instrument.

Oncolytic Virus Therapy